PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, USA.\', \'Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/jmv.27616
?:doi
?:hasPublicationType
?:journal
  • Journal of medical virology
is ?:pmid of
?:pmid
?:pmid
  • 35080027
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.978
?:rankingScore_hIndex
  • 105
is ?:relation_isRelatedTo_publication of
?:title
  • Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35080027>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35080027>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all